#VisualAbstract: Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Tag: medullary thyroid cancer
Selpercatinib may provide an effective response against RET-mutated thyroid cancer
1. Selpercatinib, a highly selective RET kinase inhibitor, was effective in antitumor activity against medullary thyroid cancer. 2. Selpercatinib caused ...